CHIP-derived immune cells have been detected in solid tumor tissues from patients with CHIP,16–18 with an enrichment in non-small cell lung cancer (NSCLC),18 where they have the potential to alter the local microenvironment and influence tumor evolution.19,20 While more than 20% of patients with cancer have CHIP,14,15 the impact of tumor-infiltrating immune cells with CHIP mutations on tumor progression and patient outcomes remains poorly understood. This evidence concerns the gene STUB1 and neoplasm.